Fermentalg and ADL Biopharma partner on omega 3 supplements
28 Sep 2018 --- Fermentalg, a manufacturer of microalgae for human nutrition and health, and ADL BioPharma are entering a long-term manufacturing contract to produce Fermentalg's algal oil DHA ORIGINS.
“This long-term contract, following the signature of a major commercial partnership, secures our supply of our high-value DHA ORIGINS 550, the algal DHA with the highest natural concentration on the market. ADL Biopharma's scale, extensive experience and capabilities in fermentation and extraction technologies will support our commitment to become one of the world's largest producer of algal DHA,” says Philippe Lavielle, CEO of Fermentalg.
ADL BioPharma and Fermentalg plan to complete the validation and technology transfer phase before the end of 2018, following which ADL will dedicate a part of its fermentation capacity to Fermentalg productions, allowing it to supply hundreds of tons to the growing DHA ORIGINS 550 market.
ADL BioPharma, a total subsidiary of ADL Bionatur group, is a European player in the biotech contract manufacturing fermentation industry. The company owns and operates an advanced industrial biotechnology plant in Southern Europe with a current fermentation capacity of 2,400 m3.
“This is the fourth long-term CMO contract that we signed during the latest ten months, guaranteeing more than 85 percent of our current business plan for the next years. This is a validation of our assumptions about the market needs for state of the art fermentation industrial sites. We are very proud of the quality of our customers in terms of innovation and quality. Fermentalg is doing a great development with their product, targeting the premium algal omega 3 market worldwide for human nutrition, and we are happy to be their partner for a key part of their value chain,” says Pilar de la Huerta, CEO of ADL BioPharma.
Fermantalg recently announced that it was also partnering with DSM Nutritional Product on ORIGINS DHA.
